UCB FIRST LOOK : Data Reveal Underlines Bimzelx' Potential in HS
UCB revealed new pooled data from its BE HEARD I and II trials on bime treatment in HS. The most interesting new data point is 3/10 patients achieving HiSCR100 at 48 weeks, a very stringent endpoint in a complex disease. We believe that bime has a right to play (best-in-class potential) versus competition in the HS space, and maintain a bullish view on the asset while we await further FDA news for PsO. We re-iterate our € 110 TP and Buy rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.